Relmada Therapeutics, Inc.
RLMDRelmada Therapeutics, Inc. in brief
Relmada Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Coral Gables, Florida, USA. It was founded in 2004. Its market value was $337 M on 20 October 2026, which makes it the 14,301st largest listed company in the world and the 2,801st largest in the USA on this site. It employs about 10 people and Sergio Traversa is its chief executive. Its shares trade under the symbol RLMD (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a Late Stage Biotech company focused on addressing diseases of the central nervous system (CNS). The headquarters is in USA.
Relmada Therapeutics, Inc. timeline
- 2004
- 🏁· approximateFounded
- 2012
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- ✎Renamed Relmada Therapeutics, Inc.Formerly Camp Nine, Inc..
Events of Relmada Therapeutics, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,413 (Jan 2020) · #2,714 (Jan 2021) · #3,101 (Jan 2022) · #4,361 (Dec 2022) · #4,438 (Jul 2023) · #3,498 (Jan 2024) · #1,471 (Mar 2026) · #2,521 (Aug 2026) · #2,787 (Oct 2026) · #2,805 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.9×
- Free cash flow yield
- -62.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -66.3%
- Liabilities / assets
- 8.0%
- Revenue growth
- 0.0%
- Profit per employee
- $-5.7 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-59M | $-57M | — |
| Dec 2024 | — | — | $-84M | $-80M | — |
| Dec 2023 | — | — | $-104M | $-99M | — |
| Dec 2022 | — | — | $-161M | $-157M | — |
| Dec 2021 | — | — | $-126M | $-126M | — |
| Dec 2020 | — | — | $-61M | $-59M | — |
| Dec 2019 | — | — | $-15M | $-15M | — |
| Jun 2018 | — | — | $-7M | $-9M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-46M | — | — | $-1.45 | — |
| Dec 2024 | $-52M | — | — | $-2.65 | — |
| Dec 2023 | $-52M | — | — | $-3.28 | — |
| Dec 2022 | $-104M | — | — | $-5.30 | — |
| Dec 2021 | $-92M | — | — | $-7.16 | — |
| Dec 2020 | $-28M | $182M | $-210M | $-3.81 | — |
| Dec 2019 | $-12M | $85M | $-97M | $-1.62 | — |
| Jun 2018 | $-6M | $0M | $-6M | $-0.71 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-14M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Sep 8, 20268-KCurrent reportOther events
- Aug 6, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Jul 28, 20268-KCurrent reportRegulation FD disclosure
- May 28, 20268-KCurrent reportBylaws amended · Shareholder vote
- May 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- May 12, 202610-QQuarterly report · period to Mar 2026
- Apr 17, 2026DEF 14AProxy statement
- Mar 20, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Mar 19, 202610-KAnnual report · period to Dec 2025
Official filings of Relmada Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-59 M
- Net income
- $-57 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $94 M
- Total liabilities
- $7 M
- Total equity
- $87 M
As of December-2025
Top 100 institutional investors in Relmada Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd. | 11,164,803 | — | 10.46% | $42 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 7,576,990 | +150,210 (+2.02%) | 7.10% | $29 M | Nov 13, 2026 |
| 3 | Venrock Adviser, LLC | 7,445,050 | +600,745 (+8.78%) | 6.98% | $28 M | Nov 16, 2026 |
| 4 | Spruce Street Capital LP | 6,912,191 | +520,863 (+8.15%) | 6.48% | $26 M | Nov 13, 2026 |
| 5 | Jones Hill Capital LP | 5,237,628 | +1,582,553 (+43.30%) | 4.91% | $20 M | Nov 13, 2026 |
| 6 | Adage Capital Partners GP, L.L.C. | 4,763,158 | 0 (0.00%) | 4.46% | $18 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 4,357,967 | -102,243 (-2.29%) | 4.08% | $16 M | Nov 13, 2026 |
| 8 | Ameriprise Financial Inc | 3,722,041 | +1,784,069 (+92.06%) | 3.49% | $14 M | Nov 16, 2026 |
| 9 | Sio Capital Management, LLC | 3,629,844 | +2,626,282 (+261.70%) | 3.40% | $14 M | Nov 16, 2026 |
| 10 | Squadron Capital Management LLC | 3,500,000 | -3,850,000 (-52.38%) | 3.28% | $13 M | Nov 16, 2026 |
| 11 | Millennium Management LLC | 3,345,573 | +983,746 (+41.65%) | 3.14% | $13 M | Nov 16, 2026 |
| 12 | State Street Corp | 3,309,355 | +791,805 (+31.45%) | 3.10% | $12 M | Nov 12, 2026 |
| 13 | Geode Capital Management, LLC | 2,361,437 | -131,136 (-5.26%) | 2.21% | $9 M | Nov 6, 2026 |
| 14 | Commodore Capital LP | 2,350,000 | +925,000 (+64.91%) | 2.20% | $9 M | Nov 16, 2026 |
| 15 | Franklin Templeton Inc | 2,248,263 | New | 2.11% | $8 M | Nov 12, 2026 |
| 16 | Driehaus Capital Management LLC | 2,132,053 | 0 (0.00%) | 2.00% | $8 M | Nov 16, 2026 |
| 17 | Qube Research & Technologies Ltd | 1,911,342 | +1,219,797 (+176.39%) | 1.79% | $7 M | Nov 13, 2026 |
| 18 | Eventide Asset Management, LLC | 1,858,416 | 0 (0.00%) | 1.74% | $7 M | Nov 13, 2026 |
| 19 | Orbimed Advisors LLC | 1,670,079 | -1,961,116 (-54.01%) | 1.57% | $6 M | Nov 16, 2026 |
| 20 | Balyasny Asset Management L.P. | 1,503,760 | -16,928 (-1.11%) | 1.41% | $6 M | Nov 16, 2026 |
| 21 | Ikarian Capital, LLC | 1,448,359 | -700,000 (-32.58%) | 1.36% | $5 M | Nov 16, 2026 |
| 22 | Polar Capital Holdings Plc | 1,336,318 | -4,110 (-0.31%) | 1.25% | $5 M | Nov 16, 2026 |
| 23 | Vanguard Portfolio Management LLC | 1,180,661 | +282,463 (+31.45%) | 1.11% | $4 M | Nov 13, 2026 |
| 24 | Walleye Capital LLC | 1,015,489 | +399,251 (+64.79%) | 0.95% | $4 M | Nov 13, 2026 |
| 25 | Opaleye Management Inc. | 1,000,000 | +65,000 (+6.95%) | 0.94% | $4 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Corient Private Wealth LP | 912,915 | New | 0.86% | $3 M | Nov 16, 2026 |
| 27 | Goldman Sachs Group Inc | 880,889 | +113,265 (+14.76%) | 0.83% | $3 M | Nov 16, 2026 |
| 28 | Great Point Partners LLC | 842,106 | 0 (0.00%) | 0.79% | $3 M | Nov 16, 2026 |
| 29 | Northern Trust Corp | 759,502 | -26,755 (-3.40%) | 0.71% | $3 M | Nov 16, 2026 |
| 30 | Vanguard Fiduciary Trust Co | 690,663 | -43,528 (-5.93%) | 0.65% | $3 M | Nov 13, 2026 |
| 31 | AdvisorShares Investments LLC | 670,861 | +231,960 (+52.85%) | 0.63% | $3 M | Nov 9, 2026 |
| 32 | Marshall Wace, LLP | 603,357 | -1,643,482 (-73.15%) | 0.57% | $2 M | Nov 13, 2026 |
| 33 | Bank Of America Corp /de/ | 581,011 | -231,048 (-28.45%) | 0.54% | $2 M | Nov 16, 2026 |
| 34 | ADAR1 Capital Management, LLC | 551,918 | +100,000 (+22.13%) | 0.52% | $2 M | Nov 16, 2026 |
| 35 | Renaissance Technologies LLC | 503,192 | +445,392 (+770.57%) | 0.47% | $2 M | Nov 12, 2026 |
| 36 | Knott David M Jr | 480,000 | +29,000 (+6.43%) | 0.45% | $2 M | Nov 12, 2026 |
| 37 | Citadel Advisors LLC | 442,103 | -619,562 (-58.36%) | 0.41% | $2 M | Nov 16, 2026 |
| 38 | Los Angeles Capital Management LLC | 420,451 | +264,738 (+170.02%) | 0.39% | $2 M | Nov 12, 2026 |
| 39 | HighVista Strategies LLC | 419,299 | -26,500 (-5.94%) | 0.39% | $2 M | Nov 13, 2026 |
| 40 | D. E. Shaw & Co., Inc. | 418,387 | +308,913 (+282.18%) | 0.39% | $2 M | Nov 16, 2026 |
| 41 | Birchview Capital, LP | 408,100 | 0 (0.00%) | 0.38% | $2 M | Nov 13, 2026 |
| 42 | UBS Group AG | 405,539 | +247,506 (+156.62%) | 0.38% | $2 M | Nov 10, 2026 |
| 43 | Parsons Capital Management Inc/ri | 404,099 | +50,030 (+14.13%) | 0.38% | $2 M | Oct 28, 2026 |
| 44 | Boothbay Fund Management, LLC | 372,300 | -192,459 (-34.08%) | 0.35% | $1 M | Nov 16, 2026 |
| 45 | Bank of New York Mellon Corp | 361,922 | +66,299 (+22.43%) | 0.34% | $1 M | Nov 5, 2026 |
| 46 | Diadema Partners LP | 361,367 | 0 (0.00%) | 0.34% | $1 M | Nov 16, 2026 |
| 47 | Wellington Management Group LLP | 336,070 | +272,270 (+426.76%) | 0.32% | $1 M | Nov 16, 2026 |
| 48 | Woodline Partners LP | 328,421 | 0 (0.00%) | 0.31% | $1 M | Nov 16, 2026 |
| 49 | Seven Grand Managers, LLC | 315,788 | 0 (0.00%) | 0.30% | $1 M | Nov 16, 2026 |
| 50 | Deutsche Bank AG\ | 307,360 | -11,542 (-3.62%) | 0.29% | $1 M | Nov 6, 2026 |
| 51 | Eversept Partners, LP | 291,905 | +198,713 (+213.23%) | 0.27% | $1 M | Nov 16, 2026 |
| 52 | Charles Schwab Investment Management Inc | 282,719 | +2 (0.00%) | 0.27% | $1 M | Nov 16, 2026 |
| 53 | FMR LLC | 276,072 | +275,912 (+172445.00%) | 0.26% | $1 M | Nov 10, 2026 |
| 54 | Morgan Stanley | 254,865 | +172,042 (+207.72%) | 0.24% | $1 M | Nov 13, 2026 |
| 55 | Nuveen, LLC | 225,067 | 0 (0.00%) | 0.21% | $1 M | Nov 10, 2026 |
| 56 | Gsa Capital Partners LLP | 199,885 | +58,442 (+41.32%) | 0.19% | $1 M | Nov 16, 2026 |
| 57 | Profund Advisors LLC | 195,555 | +168,229 (+615.64%) | 0.18% | $1 M | Oct 29, 2026 |
| 58 | Squarepoint Ops LLC | 183,943 | New | 0.17% | $1 M | Nov 9, 2026 |
| 59 | Russell Investments Group, Ltd. | 165,861 | +158,299 (+2093.35%) | 0.16% | $1 M | Nov 6, 2026 |
| 60 | Two Sigma Investments, LP | 158,932 | -55,983 (-26.05%) | 0.15% | $1 M | Nov 16, 2026 |
| 61 | Alps Advisors Inc | 140,319 | +33,863 (+31.81%) | 0.13% | $1 M | Nov 3, 2026 |
| 62 | Rhumbline Advisers | 119,453 | +1,345 (+1.14%) | 0.11% | $0 M | Nov 10, 2026 |
| 63 | Invesco Ltd. | 117,571 | +27,900 (+31.11%) | 0.11% | $0 M | Nov 12, 2026 |
| 64 | XTX Topco Ltd | 106,657 | New | 0.10% | $0 M | Nov 16, 2026 |
| 65 | LMR Partners LLP | 100,645 | +45,045 (+81.02%) | 0.09% | $0 M | Nov 16, 2026 |
| 66 | X-Square Capital, LLC | 100,000 | 0 (0.00%) | 0.09% | $0 M | Nov 10, 2026 |
| 67 | Mgo One Seven LLC | 100,000 | 0 (0.00%) | 0.09% | $0 M | Oct 28, 2026 |
| 68 | American Century Companies Inc | 91,710 | +24,362 (+36.17%) | 0.09% | $0 M | Nov 12, 2026 |
| 69 | Price T Rowe Associates Inc /MD/ | 77,668 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 70 | AQR Capital Management LLC | 74,490 | New | 0.07% | $0 M | Nov 16, 2026 |
| 71 | Algert Global LLC | 63,140 | New | 0.06% | $0 M | Nov 17, 2026 |
| 72 | Quantbot Technologies LP | 58,434 | New | 0.05% | $0 M | Nov 12, 2026 |
| 73 | Pale Fire Capital SE | 51,650 | +20,000 (+63.19%) | 0.05% | $0 M | Nov 13, 2026 |
| 74 | Citigroup Inc | 48,656 | -23,097 (-32.19%) | 0.05% | $0 M | Nov 4, 2026 |
| 75 | Virtus Investment Advisers, LLC | 47,719 | -1,483 (-3.01%) | 0.04% | $0 M | Nov 12, 2026 |
| 76 | apricus wealth, LLC | 47,462 | 0 (0.00%) | 0.04% | $0 M | Oct 26, 2026 |
| 77 | MetLife Investment Management, LLC | 47,257 | -8,305 (-14.95%) | 0.04% | $0 M | Nov 16, 2026 |
| 78 | Jpmorgan Chase & Co | 47,138 | +7,935 (+20.24%) | 0.04% | $0 M | Nov 12, 2026 |
| 79 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 46,315 | +2,955 (+6.82%) | 0.04% | $0 M | Nov 16, 2026 |
| 80 | Stempoint Capital LP | 44,129 | -1,415,964 (-96.98%) | 0.04% | $0 M | Nov 16, 2026 |
| 81 | Massachusetts Financial Services Co /ma/ | 40,163 | New | 0.04% | $0 M | Nov 12, 2026 |
| 82 | Barclays PLC | 39,798 | -11,436 (-22.32%) | 0.04% | $0 M | Nov 6, 2026 |
| 83 | Alliancebernstein L.P. | 39,600 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 84 | Trexquant Investment LP | 39,087 | -4,659 (-10.65%) | 0.04% | $0 M | Nov 16, 2026 |
| 85 | Persistent Asset Partners Ltd | 38,613 | -47,830 (-55.33%) | 0.04% | $0 M | Nov 13, 2026 |
| 86 | Creative Planning | 38,096 | New | 0.04% | $0 M | Nov 2, 2026 |
| 87 | Vanguard Global Advisers, LLC | 37,993 | -6,170 (-13.97%) | 0.04% | $0 M | Nov 13, 2026 |
| 88 | Rafferty Asset Management, LLC | 34,509 | +14,606 (+73.39%) | 0.03% | $0 M | Nov 13, 2026 |
| 89 | Susquehanna International Group, LLP | 33,085 | +2,977 (+9.89%) | 0.03% | $0 M | Nov 16, 2026 |
| 90 | AlTi Global, Inc. | 31,975 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 91 | LPL Financial LLC | 29,399 | -19,172 (-39.47%) | 0.03% | $0 M | Nov 6, 2026 |
| 92 | Wells Fargo & Company/mn | 28,739 | -57,524 (-66.68%) | 0.03% | $0 M | Nov 16, 2026 |
| 93 | Police & Firemen's Retirement System of New Jersey | 27,890 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 94 | New York State Common Retirement Fund | 26,000 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 95 | Verdad Advisers, LP | 25,824 | -61,170 (-70.32%) | 0.02% | $0 M | Nov 16, 2026 |
| 96 | Manufacturers Life Insurance Company, The | 25,028 | +1 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 97 | Robertson Stephens Wealth Management, LLC | 25,000 | 0 (0.00%) | 0.02% | $0 M | Oct 16, 2026 |
| 98 | BNP Paribas Financial Markets | 24,243 | +9,814 (+68.02%) | 0.02% | $0 M | Nov 12, 2026 |
| 99 | CV Advisors LLC | 20,000 | New | 0.02% | $0 M | Oct 13, 2026 |
| 100 | Royal Bank Of Canada | 18,731 | +15,665 (+510.93%) | 0.02% | $0 M | Nov 16, 2026 |
Mutual funds holding Relmada Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 3.17 M | $22 M | 3.0% | <0.01% | +45% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 2.09 M | $14 M | 2.0% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.20 M | $8 M | 1.1% | <0.01% | +46% | Jun 30, 2026 |
| 🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC | 1.02 M | $7 M | 0.95% | 0.39% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 865,607 | $6 M | 0.81% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.04 M | $5 M | 0.97% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P Pharmaceuticals ETFSSGA Funds Management, Inc. | 655,062 | $5 M | 0.61% | 1.1% | new | Jun 30, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 788,718 | $4 M | 0.74% | 0.36% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 379,189 | $3 M | 0.36% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 317,798 | $2 M | 0.30% | 0.14% | new | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 176,772 | $1 M | 0.17% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 229,629 | $1 M | 0.22% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 163,750 | $1 M | 0.15% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 144,336 | $1 M | 0.14% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 111,592 | $1 M | 0.10% | <0.01% | −3.8% | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 102,572 | $1 M | 0.10% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 125,269 | $1 M | 0.12% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 88,602 | $1 M | 0.08% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 67,900 | $0 M | 0.06% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 62,100 | $0 M | 0.06% | <0.01% | +37% | May 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 79,940 | $0 M | 0.07% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 62,337 | $0 M | 0.06% | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 47,624 | $0 M | 0.04% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 43,534 | $0 M | 0.04% | <0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 42,348 | $0 M | 0.04% | <0.01% | +9.7% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 41,528 | $0 M | 0.04% | <0.01% | +1022% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 53,081 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 50,019 | $0 M | 0.05% | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 45,005 | $0 M | 0.04% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 32,500 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 31,500 | $0 M | 0.03% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 29,782 | $0 M | 0.03% | <0.01% | new | May 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 29,842 | $0 M | 0.03% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 29,606 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 38,208 | $0 M | 0.04% | <0.01% | +70% | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 27,096 | $0 M | 0.03% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P. | 31,640 | $0 M | 0.03% | 0.05% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 21,218 | $0 M | 0.02% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 21,040 | $0 M | 0.02% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 19,223 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 19,146 | $0 M | 0.02% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 15,400 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 15,400 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 14,857 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 14,288 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 14,260 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 12,776 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 16,509 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 11,527 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 8,615 | $0 M | <0.01% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 8,582 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 11,074 | $0 M | 0.01% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 10,637 | $0 M | <0.01% | <0.01% | +54% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust | 7,280 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 7,562 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 6,413 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 8,360 | $0 M | <0.01% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 7,734 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 7,699 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 5,817 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 4,132 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 3,772 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 SIMT Tax-Managed Small/Mid Cap FundSEI Institutional Managed Trust | 3,407 | $0 M | <0.01% | <0.01% | −96% | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,303 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 2,387 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 2,546 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC | 1,807 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,655 | $0 M | <0.01% | <0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 2,078 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 620 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 572 | $0 M | <0.01% | <0.01% | +63% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 71 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Relmada Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Maged ShenoudaChief Financial Officer | Buy | +79,800 | $4.250 | $339 K | 1.00 M | Form 4 |
| filed | Sergio TraversaChief Executive Officer, Director | Buy | +100,000 | $4.100 | $410 K | 1.50 M | Form 4 |
| filed | Maged ShenoudaChief Financial Officer | Buy | +120,200 | $4.200 | $505 K | 920,200 | Form 4 |
| filed | Sergio TraversaChief Executive Officer, Director | Buy | +100,000 | $4.180 | $418 K | 1.40 M | Form 4 |
| filed | Sergio TraversaChief Executive Officer, Director | Buy | +27,500 | $4.120 | $113 K | 1.30 M | Form 4 |
| filed | Maged ShenoudaChief Financial Officer | Buy | +11,665 | $4.120 | $48 K | 800,000 | Form 4 |
| filed | Paul Edward KellyChief Operating Officer, Director | Buy | +90,000 | $2.200 | $198 K | 502,295 | Form 4 |
| filed | Maged ShenoudaChief Financial Officer | Buy | +500,000 | $2.200 | $1.1 M | 788,335 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Relmada Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2026 | Q3 2026 | $0M |
| Q2 2026 | Q2 2026 | $6.5M |
| Q1 2026 | Q1 2026 | $3.4M |
Trading halts
- 2025-04-28 17:27 UTC, code LUDP, resumed 17:32 UTC
- 2024-12-09 12:25 UTC, code T3, resumed 13:00 UTC
- 2024-12-04 12:25 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 327,973 shares at $3.16
- : 328,085 shares at $3.10
- : 228,185 shares at $3.20
- : 128,421 shares at $3.24
- : 300,758 shares at $3.17
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Relmada Therapeutics, Inc. scorecard#
Passes 2 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 20, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.9×Price to book 3.9× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-62.2%Free cash flow is -62.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.45 vs -2.65Diluted EPS -1.45 in fiscal 2025 against -2.65 the year before (report's currency).
- ✓Net income higher than five years earlier-$57 M-$57 M in fiscal 2025 against -$59 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$57 MNet income -$57 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-94.1%-94.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities14.6×Current ratio 14.62 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year30.9%Diluted shares up 30.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Relmada Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Jun 30, 2019 | FY 2018to Jun 30, 2018 | FY 2017to Jun 30, 2017 | FY 2016to Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | 27−41.8%— | 46−15.7%— | 55−51.6%— | 113+25.1%— | 91+152%— | 36+412%— | 7.0+139%— | 2.9+127%— | 1.3−79.2%— | 6.2—— | |
| General and administrative | 32−14.6%— | 38−22.9%— | 49+2.0%— | 48+36.6%— | 35+41.1%— | 25+336%— | 5.7+43.5%— | 4.0−32.9%— | 5.9−40.8%— | 10—— | |
| Operating expenses | 59−29.6%— | 84−19.1%— | 104−35.7%— | 161+28.3%— | 126+107%— | 61+378%— | 13+84.0%— | 6.9−4.2%— | 7.2−55.5%— | 16—— | |
| Operating income | −59—— | −84—— | −104—— | −161—— | −126—— | −61—— | −13—— | −6.9—— | −7.2—— | −16—— | |
| Interest and finance income | 1.4−60.5%— | 3.5−31.5%— | 5.2—— | — | — | — | — | — | — | — | |
| Net interest income | — | — | 5.2+93.7%— | 2.7+122%— | 1.2−14.3%— | 1.4—— | −0.8—— | −1.3—— | −0.0−131%— | 0.0—— | |
| Share of profit of associates | — | — | — | −0.6—— | −0.6—— | — | — | — | — | — | |
| Other non-operating income (expense) | 1.7−56.2%— | 3.9−20.3%— | 4.9+16.8%— | 4.2—— | −0.0−103%— | 1.4—— | −4.6—— | −2.0−319%— | 0.9−93.0%— | 13—— | |
| Net income including minority interests | — | — | — | — | −126—— | −59—— | −17—— | −9.0—— | — | — | |
| Net income attributable to shareholders | −57—— | −80—— | −99—— | −157—— | −126—— | −59—— | −17—— | −9.0—— | −6.3—— | −3.0—— | |
| Earnings per share, basic | -1.45—— | -2.65—— | -3.28—— | -5.30—— | -7.16—— | -3.81—— | -2.74r-0.69—— | -0.71—— | -0.52—— | -0.26—— | |
| Earnings per share, diluted | -1.45—— | -2.65—— | -3.28—— | -5.30—— | -7.16—— | -3.81—— | -2.74r-0.69—— | -0.71—— | -0.52—— | -0.26—— | |
| Shares, weighted average (basic) | 39+30.9%— | 30+0.2%— | 30+1.6%— | 30+68.8%— | 18—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 39+30.9%— | 30+0.2%— | 30+1.6%— | 30+68.8%— | 18+12.6%— | 16+147%— | 6.3r25−49.7%— | 13+3.9%— | 12+4.1%— | 12—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 3.5−9.3%3.7% | 3.9−5.7%8.4% | 4.1−24.2%4.2% | 5.4−87.9%3.5% | 44+1681%19.9% | 2.5−72.9%2.1% | 9.2+312%90.2% | 2.2+30.9%73.5% | 1.7−79.9%60.3% | 8.5—83.0% | |
| Short-term investments | 90+118%95.2% | 41−55.5%89.6% | 92−35.5%94.5% | 143−14.7%93.5% | 167+46.1%75.0% | 115—97.0% | — | — | — | — | |
| Receivables | — | — | — | 0.5—0.3% | — | — | — | — | — | — | |
| Other current assets | — | — | — | — | — | — | — | — | — | 0.4r0.8—3.8% | |
| Current assets | 94+105%100.0% | 46−53.0%100.0% | 98−36.2%100.0% | 153−31.5%100.0% | 223+89.1%100.0% | 118+1083%99.9% | 10.0+265%97.7% | 2.7+10.6%89.8% | 2.5−73.4%87.2% | 9.3—90.8% | |
| Property, plant and equipment | — | — | — | — | — | 0.0−82.6%0.0% | 0.0−40.3%0.1% | 0.0+422%0.4% | 0.0−99.6%0.1% | 0.5—5.2% | |
| Total assets | 94+105%100% | 46−53.0%100% | 98−36.2%100% | 153−31.5%100% | 223+89.0%100% | 118+1056%100% | 10+235%100% | 3.0+7.4%100% | 2.8−72.3%100% | 10—100% | |
| Accounts payable | 1.6−62.0%1.7% | 4.1+17.8%9.0% | 3.5−33.4%3.6% | 5.3−53.0%3.4% | 11+34.1%5.0% | 8.3+803%7.1% | 0.9+20.8%9.0% | 0.8+44.5%25.1% | 0.5−58.0%18.7% | 1.3—12.3% | |
| Customer deposits | — | — | — | — | — | — | 9.2—90.2% | — | — | — | |
| Current liabilities | 6.4−37.5%6.8% | 10−15.6%22.5% | 12−2.2%12.5% | 12−17.2%8.2% | 15+19.5%6.7% | 13+384%10.7% | 2.6−55.9%25.5% | 5.9+329%194% | 1.4−55.0%48.5% | 3.1—29.9% | |
| Total liabilities | 7.5−27.2%8.0% | 10−15.6%22.5% | 12−2.2%12.5% | 12−17.2%8.2% | 15+19.5%6.7% | 13+384%10.7% | 2.6−69.6%25.5% | 8.6+522%281% | 1.4−57.0%48.5% | 3.2—31.3% | |
| Retained earnings | −698—−743% | −641—−1399% | −561—−575% | −462—−302% | −305—−137% | −179—−152% | −112—−1093% | −94—−3095% | −85—−3010% | −79—−772% | |
| Shareholders' equity | 87+144%92.0% | 36−58.4%77.5% | 85−39.2%87.5% | 140−32.6%91.8% | 208+97.3%93.3% | 106+1287%89.3% | 7.6—74.5% | −5.5−478%−181% | 1.5−79.3%51.5% | 7.0—68.7% | |
| Total equity | — | — | — | — | 208+97.3%93.3% | 106—89.3% | — | — | — | — | |
| Total liabilities and equity | 94+105%100% | 46−53.0%100% | 98−36.2%100% | 153−31.5%100% | 223+89.0%100% | 118+1056%100% | 10+235%100% | 3.0+7.4%100% | 2.8−72.3%100% | 10—100% | |
| Shares outstanding | 73+143%— | 30+0.2%— | 300.0%— | 30+8.5%— | 28+69.8%— | 16+67.6%— | 9.7r39−22.4%— | 13+0.2%— | 13+4.1%— | 12—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 14−53.9%— | 30−31.1%— | 44−0.9%— | 44+9.1%— | 40+94.9%— | 21+1611%— | 1.2+134%— | 0.5−26.5%— | 0.7−29.7%— | 1.0—— | |
| Cash from operating activities | −46—— | −52—— | −52—— | −104—— | −92—— | −28—— | −10—— | −6.0—— | −6.5—— | −13—— | |
| Capital expenditure | — | — | — | — | — | −182—— | — | −0.0—— | −0.0—— | −0.6—— | |
| Cash from investing activities | −48−193%— | 52+2.2%— | 50+156%— | 20—— | −54—— | −34—— | — | −0.0—— | −0.0—— | −0.6—— | |
| Shares issued | 94—— | — | — | 43−76.9%— | 185+833%— | 20r18+10.9%— | 18—— | — | — | — | |
| Cash from financing activities | 94—— | −0.0—— | −0.1−100%— | 45−76.0%— | 188+560%— | 28+62.9%— | 17+167%— | 6.5—— | −0.3—— | −0.3—— | |
| Change in cash | — | — | — | — | — | — | 7.0+1220%— | 0.5—— | −6.8—— | −14—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 34+13.3%— | 9.2+128%— | 8.4+198%— | 8.1−32.3%— | 8.1*−26.6%— | 4.0−63.8%— | 2.8−73.7%— | 12−10.2%— | 11*−25.4%— | 11—— | 11—— | 13—— | 15*—— | |
| General and administrative | 34+21.7%— | 3.9−38.3%— | 6.6−10.6%— | 11+81.5%— | 12*+51.8%— | 6.3−47.0%— | 7.4−8.6%— | 6.3−35.3%— | 8.1*−33.1%— | 12—— | 8.1—— | 9.7—— | 12*—— | |
| Operating expenses | 68+17.4%— | 13+26.8%— | 15+46.9%— | 19+6.8%— | 20*+6.6%— | 10−55.1%— | 10−45.7%— | 18−20.7%— | 19*−28.9%— | 23—— | 19—— | 23—— | 27*—— | |
| Operating income | −68—— | −13—— | −15—— | −19—— | −20*—— | −10—— | −10—— | −18—— | −19*—— | −23—— | −19—— | −23—— | −27*—— | |
| Interest and finance income | 5.9+256%— | 2.3+821%— | 2.3+616%— | 1.0+118%— | 0.4*−40.8%— | 0.2−71.2%— | 0.3−66.6%— | 0.4−58.3%— | 0.7*−48.0%— | 0.9—— | 1.0—— | 1.1—— | 1.3*—— | |
| Net interest income | — | — | — | — | — | — | — | — | — | — | — | — | 1.3*—— | |
| Other non-operating income (expense) | 2.2+32.3%— | −0.8−425%— | 2.1+491%— | 0.4−37.8%— | 0.5*+11.2%— | 0.2−81.6%— | 0.4−66.2%— | 0.7−43.2%— | 0.4*−74.9%— | 1.3—— | 1.1—— | 1.2—— | 1.7*—— | |
| Net income attributable to shareholders | −66—— | −14—— | −13—— | −19—— | −20*—— | −10—— | −9.9—— | −18—— | −19*—— | −22—— | −18—— | −22—— | −25*—— | |
| Earnings per share, basic | — | -0.12—— | -0.11—— | -0.22—— | — | -0.30—— | -0.30—— | -0.58—— | — | -0.72—— | -0.59—— | -0.72—— | — | |
| Earnings per share, diluted | — | -0.12—— | -0.11—— | -0.22—— | — | -0.30—— | -0.30—— | -0.58—— | — | -0.72—— | -0.59—— | -0.72—— | — | |
| Shares, weighted average (basic) | 112+239%— | 112+239%— | 112+239%— | 87+185%— | — | 33+10.0%— | 33+10.0%— | 30+0.9%— | — | 30—— | 30—— | 30—— | — | |
| Shares, weighted average (diluted) | 112+239%— | 112+239%— | 112+239%— | 87+185%— | — | 33+10.0%— | 33+10.0%— | 30+0.9%— | — | 30—— | 30—— | 30—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 5.7—2.8% | 5.7+313%2.8% | 11+738%5.2% | 9.8+750%4.2% | 3.5−9.3%3.7% | 1.4−6.7%9.3% | 1.4−35.1%6.4% | 1.1−13.9%4.2% | 3.9−5.7%8.4% | 1.5—2.7% | 2.1—2.9% | 1.3—1.6% | 4.1—4.2% | |
| Short-term investments | 196—95.7% | 196+1471%95.7% | 206+971%94.2% | 224+765%95.3% | 90+118%95.2% | 13−76.2%84.0% | 19−71.8%91.2% | 26−68.5%93.6% | 41−55.5%89.6% | 53—94.5% | 68—96.2% | 82—97.5% | 92—94.5% | |
| Current assets | 205—99.9% | 205+1280%99.9% | 219+938%100.0% | 235+751%100.0% | 94+105%100.0% | 15−73.3%99.9% | 21−70.3%99.9% | 28−67.2%99.9% | 46−53.0%100.0% | 56—100.0% | 71—99.9% | 84—99.9% | 98—100.0% | |
| Total assets | 205—100% | 205+1280%100% | 219+937%100% | 235+750%100% | 94+105%100% | 15−73.3%100% | 21−70.3%100% | 28−67.2%100% | 46−53.0%100% | 56—100% | 71—100% | 84—100% | 98—100% | |
| Accounts payable | 2.5—1.2% | 2.5+74.7%1.2% | 2.4+76.9%1.1% | 5.7+353%2.4% | 1.6−62.0%1.7% | 1.5−38.0%9.8% | 1.4−67.4%6.4% | 1.3−75.6%4.6% | 4.1+17.8%9.0% | 2.3—4.2% | 4.2—5.9% | 5.2—6.1% | 3.5—3.6% | |
| Current liabilities | 7.8—3.8% | 7.8+49.8%3.8% | 7.4+44.5%3.4% | 13+146%5.5% | 6.4−37.5%6.8% | 5.2−35.8%34.9% | 5.1−46.2%24.3% | 5.2−57.7%18.9% | 10−15.6%22.5% | 8.1—14.5% | 9.5—13.4% | 12—14.6% | 12—12.5% | |
| Total liabilities | 12—5.6% | 12+114%5.6% | 13+142%5.7% | 17+217%7.1% | 7.5−27.2%8.0% | 5.4−33.2%36.4% | 5.2—24.5% | 5.2−57.6%18.9% | 10−15.6%22.5% | 8.1—14.5% | — | 12—14.6% | 12—12.5% | |
| Retained earnings | −744—−362% | −744—−362% | −730—−333% | −717—−305% | −698—−743% | −678—−4560% | −668—−3165% | −658—−2379% | −641—−1399% | −622—−1117% | −600—−845% | −583—−690% | −561—−575% | |
| Shareholders' equity | 194—94.4% | 194+1947%94.4% | 207+1195%94.3% | 219+875%92.9% | 87+144%92.0% | 9.5−80.1%63.6% | 16−74.1%75.5% | 22−68.9%81.1% | 36−58.4%77.5% | 48—85.5% | 61—86.6% | 72—85.4% | 85—87.5% | |
| Total liabilities and equity | 205—100% | 205+1280%100% | 219+937%100% | 235+750%100% | 94+105%100% | 15−73.3%100% | 21−70.3%100% | 28−67.2%100% | 46−53.0%100% | 56—100% | 71—100% | 84—100% | 98—100% | |
| Shares outstanding | 107—— | 107+221%— | 107+221%— | 105+216%— | 73+143%— | 33+10.0%— | 33+10.0%— | 33+10.0%— | 30+0.2%— | 30—— | 30—— | 30—— | 30—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 6.2−64.5%— | 1.0−71.6%— | 0.9−73.8%— | 1.0−73.2%— | 3.3r2.4*−51.3%— | 3.6−54.6%— | 3.4−52.2%— | 3.6r4.5−56.9%— | 6.7*−32.0%— | 7.9*—— | 7.2*—— | 8.3—— | 9.9*—— | |
| Cash from operating activities | −52—— | −13*—— | −9.6*—— | −15—— | −15*—— | −6.7*—— | −6.4*—— | −18—— | −8.8*—— | −17*—— | −13*—— | −13—— | −10*—— | |
| Cash from investing activities | −188−567%— | 7.0*+3.0%— | 18*+163%— | −135−980%— | −77*−778%— | 6.8*−58.2%— | 6.7*−52.3%— | 15+52.7%— | 11*+46.6%— | 16*—— | 14*—— | 10—— | 7.7*—— | |
| Shares issued | — | 0*—— | — | — | — | — | — | — | — | — | — | — | — | |
| Shares bought back | — | 0*—— | −6.5*—— | −3.4—— | — | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 244—— | 0.0*—— | −6.4*—— | 157—— | 94*—— | 0*—— | — | — | −0.2*—— | −0.1*—— | 0*—— | 0.2—— | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Relmada Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Sergio Traversa | $8.9 M | $19.5 M | $5.6 M | $15 |
| 2024Sergio Traversa | $1.8 M | −$699 K | $988 K | $2 |
| 2023Sergio Traversa | $2.1 M | $174 K | $1.2 M | $13 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Relmada Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 2 · Auditor changed 1 · Directors and officers 2 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Agreement ended | 8-K | |
| Shareholder vote | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2019 | $8 M | Private placement after listing | $2 to $10 million | 116 | equity, options | SEC |
| May 2019 | $3 M | Private placement after listing | $2 to $10 million | 43 | equity, options | SEC |
| Oct 2018 | $6 M | Private placement after listing | $2 to $10 million | 66 | equity, options | SEC |
| Sep 2017 | $7 M | Private placement after listing | $2 to $10 million | 65 | debt, options | SEC |
| Jun 2014 | $11 M | No. 1 | $10 to $50 million | 236 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Relmada Therapeutics, Inc.#
$100 K spent on lobbying the US Congress and federal agencies in 2022.
Lobbying firms hired in 2022
THE KPM GROUP DC LLC $100 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $100 K | — | 4 |
| 2021 | $30 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Relmada Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
Discuss Relmada Therapeutics, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
Relmada Therapeutics, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $14 million.
- Mutual funds: 71 funds hold $92 millionautomatic update · Jul 31, 2026
71 mutual funds in 1 country hold shares of Relmada Therapeutics, Inc. worth $92 million, about 13.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 64 funds added shares and 2 sold; on balance they bought $65 million. Share splits are not counted as trading.
How Relmada Therapeutics, Inc. compares in Biotechnology
- Market cap$337 M · higher than 53% of 726
- Revenue growth0.0% · higher than 42% of 438
- Price / book3.9× · lower than 39% of 534
- FCF yield-62.2% · higher than 20% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Relmada Therapeutics, Inc.🇺🇸 | $337 M | — | — | 0.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 20, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Relmada Therapeutics, Inc.? Verify and update this profile — free
Show Relmada Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.